By Dean Seal
Deciphera Pharmaceuticals said the Phase 3 study of its treatment vimseltinib for tenosynovial giant cell tumors met its primary endpoint and all key secondary endpoints.
The biopharmaceutical company said Monday that vimseltinib, tested for patients with TGCT who aren’t amenable to surgery, showed a statistically significant and clinically meaningful improvement for patients compared with a placebo by week 25.
The study also showed meaningful improvements versus placebo in all key secondary endpoints assessed at week 25.
The drug was well-tolerated and its safety profile was consistent with previously disclosed data.
Write to Dean Seal at [email protected]
Read the full article here